Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018The HF Therapeutics Market Shows Significant Growth Until 2018
By: Rajesh Gunnam Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.9% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily due to the expected launch of novel therapies relaxin and LCZ696 during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in 2015. An increase in the treatment-seeking population, due to an increase in life expectancy and increasing health awareness among patients, which leads to earlier diagnoses, will also drive the HF therapeutics market. Apart from these, the HF therapeutics market will be driven by increases in an aging population who are more susceptible tow acute heart failure (AHF). Current competition in the HF therapeutics market is weak, primarily dominated by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol) GlobalData’s analysis suggests that the current HF therapeutics market is dominated by generics which do not serve the needs of HF patients as they do not treat the underlying cause of the disease. Drugs such as Natrecor, dopamine and dobutamine are still used to manage acute cases of HF, as are digoxin, ramipril, carvedilol, metoprolol and Diovan. However, none of these drugs are having disease modifying mechanism. Safety is another major concern with the majority of the drugs approved for HF treatment as many carry adverse effects such as, hypotension, headache, nausea, insomnia, ventricular tachycardia, and bradycardia. Natrecor, which is approved for AHF, has been linked to renal toxicity and an increased risk of death in acute cases. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData’s analysis found that there are 40 molecules under clinical development for the treatment of HF. Of these, 78% of the molecules are first-in-class (FIC), and their ability to improve cardiac function and reduce mortality in HF patients is being investigated. There are nine molecules in Phase III, making up 23% of the HF therapeutics pipeline. Out of these, 78% are FIC molecules, being developed for the treatment and management of HF. Relaxin and LCZ696 (Phase III molecules) with their novel mechanism of action, would be able improve cardiac function in HF patients. In addition to these, Lixivaptan, Aranesp (darbepoetin alfa), recombinant human neuregulin-1, Tekturna (aliskiren), and FDC formulation are also investigated to manage early stage HF. The Phase II pipeline has 16 molecules, making up 40% of the total HF therapeutics pipeline. The majority of Phase II molecules are being clinically tested for safety and efficacy in improving the cardiac function. Phase I of the HF pipeline has only five molecules, Preclinical stage contains seven molecules, and Discovery Phase comprises three molecules of the total pipeline. Industry analysis specialist, GlobalData, has released its new report, “Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global Heart Failure therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global Heart Failure therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Heart Failure sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number